FOX40 News1mon
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
Niktimvo (axatilimab-csfr) is a first-in-class ... Niktimvo based on severity of the reaction. Based on its mechanism of action, Niktimvo may cause fetal harm when administered to a pregnant ...
pharmaphorum6mon
Incyte builds GvHD presence with Niktimvo approval
Incyte licensed axatilimab from Syndax Pharma in a 2021 ... now have a new treatment option with a novel mechanism of action to help address the serious and devastating complications associated ...
Stockhouse6mon
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo(TM) (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating ... Embryo-Fetal Toxicity Based on its mechanism of action, Niktimvo may cause fetal harm when administered to a pregnant woman.
Yahoo Finance1mon
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes
– Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation and fibrosis – – Pivotal data from the AGAVE-201 trial ...